The Pulmonary Fibrosis Foundation IFP Summit, 2011: From Bench to Bedside

March 01, 2011

The Pulmonary Fibrosis Foundation (PFF) is proud to announce its first annual IPF Summit 2011: From Bench to Bedside.

The mission of the Pulmonary Fibrosis Foundation is to find a cure for idiopathic pulmonary fibrosis (IPF) by funding research, advocating for pulmonary fibrosis issues, promoting disease awareness, and providing a compassionate environment for supporting patients and their loved ones. The Summit will support our mission by improving clinical understanding of pulmonary fibrosis in the medical community, and by promoting a collaborative environment for both physicians and patients where the latest information in research and patient care is shared

Coalition for Pulmonary Fibrosis, Pulmonary Fibrosis Foundation and American Thoracic Society Announce New Research Grants for Pulmonary Fibrosis Research

March 21, 2012

The Coalition for Pulmonary Fibrosis (CPF), the Pulmonary Fibrosis Foundation (PFF), and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep medicine, today announced that the CPF and PFF will again partner with the ATS to fund Pulmonary Fibrosis (PF) research.

Pfizer's Revatio Fails To Improve Outcomes For Patients With Lung Disease: Study

May 18, 2010

Research published in NEJM suggests that Pfizer's Revatio (sildenafil) failed to meet its primary goal in a study involving patients with advanced idiopathic pulmonary fibrosis (IPF). However, the researchers noted that the improvements observed in secondary outcomes were "no doubt important to patients," given that no other treatments for the disease are currently available.

ITMN Denied FDA Approval For Drug Pirfenidone To Treat Pulmonary Fibrosis

May 04, 2010

InterMune Inc, ITMN, was refused approval for their drug that treats lung scarring by the Food and Drug Administration. The FDA asked ITMN to produce a new clinical trial that will prove the drug actually works in treating lung scarring. This announcement caused ITMN’s share to fall 80%.